Open article published on MedShr: 28th October 2020
Last updated: 28th October 2020
Every effort has been made to ensure that the information contained in this article is accurate and current at time of publication, but if you notice an error please contact email@example.com and we will aim to address this. Please find MedShr’s full terms of service here.
Since the Covid-19 pandemic has swept the globe, and after initial strict lockdown measures, governments and workplaces have had to adapt to attempt some return to normality. Although life and work have changed dramatically, with many shifting their work to home from offices, risk stratification tools have been needed to quantify biological risk to individuals. This is helpful both in workplaces, but also in clinical settings, where scoring systems can be used with patients presenting with Covid-19 like illnesses, to make predictions about the likely trajectory of their illness.
Risk stratification for populations
In the United Kingdom, the Chief Medical Officer (CMO) commissioned NHS Digital to produce a list of vulnerable people at increased risk of complications from COVID-19, who should be shielded for at least 12 weeks . A data linkage analysis was undertaken to identify individuals who should undertake ‘shielding’, and take extra precautions above normal public health measures of maintaining social distance. This resulted in the formation of two groups:
“At Risk” – a larger group of approximately 19 million, normally at risk from influenza – should practice strict social distancing
“At high risk” – a smaller sub-group of approximately 1.5 million, defined by CMO – should practice complete “shielding”
Clinical inclusion criteria deeming individuals "high risk" were determined and led to inclusion in the shielded patients list (SPL). They were as follows:
Solid organ transplant recipients who remain on long term immune suppression therapy
Cancer undergoing active chemo/ radiotherapy or radical radiotherapy for lung cancer
People having immunotherapy or other continuing antibody treatments for cancer
People having other targeted cancer treatments which affect the immune system, such as protein kinase or PARP inhibitors
People with cancers of the blood or bone marrow
People who have had bone marrow or stem cell transplants in the last 6 months, or still taking immunosuppression drugs
People with severe respiratory conditions including severe asthma and severe COPD
Cystic Fibrosis, idiopathic pulmonary Fibrosis, etc. Need to go straight through. Regardless of treatment.
People with rare diseases and inborn errors of metabolism that significantly increase the risk of infections (such as SCID, homozygous sickle cell)
People on immunosuppression therapies sufficient to significantly increase risk of infection
People who are pregnant with significant congenital heart disease
Risk assessments at work
Health and Safety Executive (HSE) have published national guidance on how to make workplaces Covid-secure during the pandemic . The key measures to mitigate risk which have been recommended include: a thorough risk assessment by employers, social distancing, cleaning, hygiene and handwashing, close collaboration with employees, working from home where possible, and special protections for vulnerable workers. To aid these decisions, a formal risk assessment matrix was also published , and extensive guidance  provided on practical measures that could be implemented to mitigate risks, including: putting in place social distancing measures, staggering shifts and providing additional handwashing facilities.
In addition to these measures, the British Medical Association created an objective risk stratification (ORS) tool for individuals not already identified as “vulnerable” by the NHS Digital Shielded Patient List . This list included factors such as age, sex, ethnicity, diabetes, obesity, cardiovascular disease, pulmonary disease, rheumatological conditions, cancer or immunosuppression (figure 1). On the basis of these factors, a score is then attributed to determine risk.
Clinical determination of at risk individuals is vital to tailor treatment, to guide management and optimise resource allocation. A study published recently in the British Medical Journal (BMJ) proposes the 4C (Coronavirus Clinical Characterisation Consortium) Mortality Score, as an easy-to-use and valid prediction tool for in-hospital mortality . The score categorises patients as being at low, intermediate, high, or very high risk of death (Figure 2).
The key benefit of such scoring systems to clinicians is to guide and support management decisions about recognising when care should be escalated.
Continue the Discussion:
Join the COVID-19 discussion groups for healthcare professionals on MedShr:
 Accessed online at: https://digital.nhs.uk/coronavirus/shielded-patient-list/methodology
 Accessed online at: https://www.hse.gov.uk/coronavirus/working-safely/index.htm
 Accessed online at: https://www.hse.gov.uk/coronavirus/assets/docs/risk-assessment.pdf
 Accessed online at: https://www.hse.gov.uk/coronavirus/working-safely/risk-assessment.htm
 Development of an Objective Risk Stratification Tool to facilitate workplace assessments of healthcare workers when dealing with the CoViD-19 pandemic. W David Strain, Janusz Jankowski, Angharad Davies, Peter MB English, Ellis Friedman, Helena McKeown, Su Sethi, Mala Rao OBE. Accessed online at: https://www.bma.org.uk/media/2768/bma-covid-19-risk-assessment-tool-july2020.pdf
 Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, Dunning J, Fairfield CJ, Gamble C, Green CA, Gupta R, Halpin S, Hardwick HE, Holden KA, Horby PW, Jackson C, Mclean KA, Merson L, Nguyen-Van-Tam JS, Norman L, Noursadeghi M, Olliaro PL, Pritchard MG, Russell CD, Shaw CA, Sheikh A, Solomon T, Sudlow C, Swann OV, Turtle LC, Openshaw PJ, Baillie JK, Semple MG, Docherty AB, Harrison EM; ISARIC4C investigators. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ. 2020 Sep 9;370:m3339. doi: 10.1136/bmj.m3339. PMID: 32907855.
Article by Dr Adam Ali, MedShr Open Editorial Team, Medical Education Fellow